LIXTClinical Trials•globenewswire•
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025
Sentiment:Positive (70)
Summary
2025 is shaping up to be a defining year for LIXTE (Nasdaq: LIXT) and its lead compound LB-100
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 14, 2025 by globenewswire